查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1242103

CAR T细胞疗法的全球市场

CAR T-cell Therapy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

CAR T细胞疗法的全球市场在2030年前将达到之前达到96亿美元

在COVID-19后改变的商务环境中，2022年20亿美元的CAR T细胞疗法的全球市场，在2022年～2030年预计将以年复合成长率 完成21.9％的速度成长，2030年之前将达到96亿美元的规模。本报告所分析之市场区隔之一的DLBCL，年复合成长率将记录18.7％，到分析期间结束时将达到46亿美元。考虑疫情后的復苏，ALL市场领域今后8年的年复合成长率将修正为25.6％。

美国市场估算为6亿1,050万美元，中国则将以年复合成长率21.4％的速度成长。

美国的CAR T细胞疗法市场在2022年估算为6亿1,050万美元。作为世界第2大经济大国的中国，在2022年～2030年年复合成长率预计将为21.4％，在2030年前将达到17亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以18.9％和18.7％的速度成长。在欧洲市场中，德国以年复合成长率15.3％成长。

调查对像企业范例

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP10884

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global CAR T-cell Therapy Market to Reach $9.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for CAR T-cell Therapy estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$9.6 Billion by 2030, growing at aCAGR of 21.9% over the period 2022-2030. DLBCL, one of the segments analyzed in the report, is projected to record 18.7% CAGR and reach US$4.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ALL segment is readjusted to a revised 25.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $610.5 Million, While China is Forecast to Grow at 21.4% CAGR

The CAR T-cell Therapy market in the U.S. is estimated at US$610.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.9% and 18.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.

Select Competitors (Total 12 Featured) -

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • CAR T-cell Therapy - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CAR T-cell Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 3: World 8-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for DLBCL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World 8-Year Perspective for DLBCL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for ALL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 7: World 8-Year Perspective for ALL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for MM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 9: World 8-Year Perspective for MM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CLL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for CLL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for FL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for FL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • CANADA
    • TABLE 16: Canada Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 17: Canada 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • JAPAN
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 18: Japan Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: Japan 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • CHINA
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: China 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • EUROPE
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 22: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 23: Europe 8-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 24: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Europe 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • FRANCE
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 26: France Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: France 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • GERMANY
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 28: Germany Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Germany 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • ITALY
    • TABLE 30: Italy Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Italy 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • UNITED KINGDOM
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 32: UK Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: UK 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 34: Rest of Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Rest of Europe 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • ASIA-PACIFIC
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 36: Asia-Pacific Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Asia-Pacific 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 38: Rest of World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Rest of World 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030

IV. COMPETITION